Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Next Previous
Trial Profile

A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluciclovine 18F (Primary)
  • Indications Prostate cancer
  • Focus Diagnostic use; Registrational
  • Acronyms FALCON
  • Sponsors Blue Earth Diagnostics

    • Most Recent Events

    • 27 Sep 2021 Post-hoc analysis results published in Blue Earth Diagnostics Media Release.
    • 27 Sep 2021 According to an Blue Earth Diagnostics media release, post-hoc analysis of data from the prospective LOCATE and FALCON were presented at the Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
    • 15 Feb 2020 Results (n=65) assessing impact on salvage radiotherapy decisions in men post-radical prostatectomy, presented at the 2020 Genitourinary Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top